-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎The content team editor of WuXi AppTec today, Janssen, a subsidiary of Johnson & Johnson, announced the final analysis results of its prostate cancer therapy Erleada (apalutamide) in the Phase 3 clinical trial TITAN.
The results of the trial showed that in patients with metastatic castration-sensitive prostate cancer (mCSPC), the addition of Erleada to androgen deprivation therapy (ADT) significantly improved the overall survival (OS) of patients compared with placebo.
Prostate cancer is the second most common type of tumor in men worldwide.
In the past ten years, the incidence of prostate cancer in China has been on the rise, and it has now become the fifth most common cancer among Chinese men.
Metastatic castration-sensitive prostate cancer (mCSPC) refers to prostate cancer that still responds to androgen deprivation therapy (ADT) and has spread to other parts of the body.
Castration endocrine therapy has always been the standard first-line treatment for advanced metastatic prostate cancer, but almost all prostate cancer (HSPC) that is sensitive to castration therapy will eventually develop into castration resistance (CRPC), and once it develops into castration resistance , The prognosis is poor, so delaying entry into castration resistance is an important treatment strategy.
Erleada is a second-generation non-steroidal androgen receptor inhibitor, which can block the action of androgens and inhibit tumor growth.
It has been approved by the FDA for the treatment of mCSPC patients.
The final analysis showed that when the median follow-up time was close to 4 years, Erleada+ADT could reduce the risk of death by 35% compared with ADT (HR=0.
65, p<0.
0001).
In this phase 3 clinical trial, patients who receive placebo treatment after unblinding can choose to switch to the Erleada group.
If one considers that patients in the placebo group join the Erleada group, the improvement in overall survival reduces the risk of death by 48%.
"TITAN's final analysis further confirmed that for patients with metastatic prostate cancer who are beginning androgen deprivation therapy, Erleada treatment can prolong overall survival and provide clear long-term clinical benefits and established safety features.
" British Columbia, Canada Said Dr.
Kim Chi, a physician oncologist at BC Cancer and the main leader of the TITAN study.
Note: This article is intended to introduce medical and health research, not to recommend treatment options.
If you need guidance on treatment plans, please go to a regular hospital for treatment.
Reference: [1] Janssen Announces Treatment with ERLEADA® (apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer.
Retrieved February 8, 2021, from https:// janssen-announces-treatment-with-erleada-apalutamide-significantly-improved-overall-survival-in-patients-with-metastatic-castration-sensitive-prostate-cancer-301224286.
html
The results of the trial showed that in patients with metastatic castration-sensitive prostate cancer (mCSPC), the addition of Erleada to androgen deprivation therapy (ADT) significantly improved the overall survival (OS) of patients compared with placebo.
Prostate cancer is the second most common type of tumor in men worldwide.
In the past ten years, the incidence of prostate cancer in China has been on the rise, and it has now become the fifth most common cancer among Chinese men.
Metastatic castration-sensitive prostate cancer (mCSPC) refers to prostate cancer that still responds to androgen deprivation therapy (ADT) and has spread to other parts of the body.
Castration endocrine therapy has always been the standard first-line treatment for advanced metastatic prostate cancer, but almost all prostate cancer (HSPC) that is sensitive to castration therapy will eventually develop into castration resistance (CRPC), and once it develops into castration resistance , The prognosis is poor, so delaying entry into castration resistance is an important treatment strategy.
Erleada is a second-generation non-steroidal androgen receptor inhibitor, which can block the action of androgens and inhibit tumor growth.
It has been approved by the FDA for the treatment of mCSPC patients.
The final analysis showed that when the median follow-up time was close to 4 years, Erleada+ADT could reduce the risk of death by 35% compared with ADT (HR=0.
65, p<0.
0001).
In this phase 3 clinical trial, patients who receive placebo treatment after unblinding can choose to switch to the Erleada group.
If one considers that patients in the placebo group join the Erleada group, the improvement in overall survival reduces the risk of death by 48%.
"TITAN's final analysis further confirmed that for patients with metastatic prostate cancer who are beginning androgen deprivation therapy, Erleada treatment can prolong overall survival and provide clear long-term clinical benefits and established safety features.
" British Columbia, Canada Said Dr.
Kim Chi, a physician oncologist at BC Cancer and the main leader of the TITAN study.
Note: This article is intended to introduce medical and health research, not to recommend treatment options.
If you need guidance on treatment plans, please go to a regular hospital for treatment.
Reference: [1] Janssen Announces Treatment with ERLEADA® (apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer.
Retrieved February 8, 2021, from https:// janssen-announces-treatment-with-erleada-apalutamide-significantly-improved-overall-survival-in-patients-with-metastatic-castration-sensitive-prostate-cancer-301224286.
html
